Literature DB >> 21574990

In children with Friedreich ataxia, muscle and ataxia parameters are associated.

Deborah A Sival1, Maria E Pouwels, Agnes Van Brederode, Natasha M Maurits, Corien C Verschuuren-Bemelmans, Ewout R Brunt, Gideon J Du Marchie Sarvaas, Renate J Verbeek, Oebele F Brouwer, Johannes H Van Der Hoeven.   

Abstract

AIM: In children with Friedreich ataxia (FRDA), ataxia is assessed using the surrogate marker the International Cooperative Ataxia Rating Scale (ICARS). We aimed to determine whether ICARS scores in children with FRDA are confounded by muscle weakness.
METHOD: In 12 children with FRDA (10 males, two females; mean age 13 y 6 mo, SD 2 y 6 mo) and 12 age-matched children without FRDA (nine males; three females), we determined the association between muscle and ataxia parameters (i.e. muscle ultrasound density (MUD), muscle force, sensory evoked potentials, and ICARS scores). Children with FRDA were included on the basis of FXN gene analysis. Children in the comparison group were included on basis of uneventful pregnancy and normal cognitive and neurological development.
RESULTS: In children with FRDA, muscle ultrasound density was homogeneously increased in the biceps, quadriceps, and tibialis anterior muscles (median 4SD). FRDA muscle weakness was significantly more pronounced in proximal than in distal muscles (-2SD vs -0.5SD respectively; p=0.004), with a stronger impairment of leg muscles than of arm muscles (-2SD vs -0. SD respectively; p=0.001). Comparing MUD between children with FRDA and an age-matched comparison group revealed a relatively strong increase in MUD in the proximal leg muscles in the FRDA group. Under the condition of persistently absent sensory evoked potentials, leg ICARS subscores in the FRDA group appeared to be positively associated with leg muscle force until a maximal plateau level of ICARS subscores was reached.
INTERPRETATION: In children with FRDA, ataxia scales based on ICARS are confounded by muscle weakness. Longitudinal ICARS evaluations in children with FRDA do not necessarily indicate altered ataxia. © The Authors. Developmental Medicine & Child Neurology
© 2011 Mac Keith Press.

Entities:  

Mesh:

Year:  2011        PMID: 21574990     DOI: 10.1111/j.1469-8749.2011.03931.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  6 in total

1.  Sensitivity of spatiotemporal gait parameters in measuring disease severity in Friedreich ataxia.

Authors:  Sarah C Milne; Darren R Hocking; Nellie Georgiou-Karistianis; Anna Murphy; Martin B Delatycki; Louise A Corben
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

Review 2.  Prevalence of ataxia in children: a systematic review.

Authors:  Kristin E Musselman; Cristina T Stoyanov; Rhul Marasigan; Mary E Jenkins; Jürgen Konczak; Susanne M Morton; Amy J Bastian
Journal:  Neurology       Date:  2013-11-27       Impact factor: 9.910

3.  Dimethyl fumarate dose-dependently increases mitochondrial gene expression and function in muscle and brain of Friedreich's ataxia model mice.

Authors:  Chun Kiu Hui; Elena N Dedkova; Claire Montgomery; Gino Cortopassi
Journal:  Hum Mol Genet       Date:  2021-02-25       Impact factor: 5.121

4.  Construct Validity and Reliability of the SARA Gait and Posture Sub-scale in Early Onset Ataxia.

Authors:  Tjitske F Lawerman; Rick Brandsma; Renate J Verbeek; Johannes H van der Hoeven; Roelineke J Lunsing; Hubertus P H Kremer; Deborah A Sival
Journal:  Front Hum Neurosci       Date:  2017-12-13       Impact factor: 3.169

5.  Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.

Authors:  Mercedes Serrano; Víctor de Diego; Jordi Muchart; Daniel Cuadras; Ana Felipe; Alfons Macaya; Ramón Velázquez; M Pilar Poo; Carmen Fons; M Mar O'Callaghan; Angels García-Cazorla; Cristina Boix; Bernabé Robles; Francisco Carratalá; Marisa Girós; Paz Briones; Laura Gort; Rafael Artuch; Celia Pérez-Cerdá; Jaak Jaeken; Belén Pérez; Belén Pérez-Dueñas
Journal:  Orphanet J Rare Dis       Date:  2015-10-26       Impact factor: 4.123

6.  Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin.

Authors:  Wolfgang Nachbauer; Sylvia Boesch; Rainer Schneider; Andreas Eigentler; Julia Wanschitz; Werner Poewe; Michael Schocke
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.